Broderick Brian C boosted its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,289 shares of the conglomerate's stock after acquiring an additional 2,879 shares during the period. Danaher accounts for about 2.9% of Broderick Brian C's portfolio, making the stock its 11th biggest position. Broderick Brian C's holdings in Danaher were worth $14,987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently bought and sold shares of the company. Howard Capital Management Group LLC grew its holdings in shares of Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate's stock worth $342,000 after purchasing an additional 48 shares during the last quarter. Ascent Group LLC lifted its holdings in Danaher by 2.9% in the third quarter. Ascent Group LLC now owns 2,270 shares of the conglomerate's stock valued at $631,000 after buying an additional 65 shares during the period. Integrated Wealth Concepts LLC boosted its position in shares of Danaher by 5.2% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 8,201 shares of the conglomerate's stock valued at $2,280,000 after purchasing an additional 408 shares in the last quarter. IHT Wealth Management LLC increased its holdings in Danaher by 20.3% in the third quarter. IHT Wealth Management LLC now owns 6,005 shares of the conglomerate's stock worth $1,666,000 after purchasing an additional 1,014 shares in the last quarter. Finally, Resurgent Financial Advisors LLC boosted its holdings in shares of Danaher by 16.7% during the 3rd quarter. Resurgent Financial Advisors LLC now owns 6,206 shares of the conglomerate's stock worth $1,725,000 after buying an additional 886 shares in the last quarter. 79.05% of the stock is owned by institutional investors.
Insiders Place Their Bets
In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company's stock, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.10% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on DHR shares. Scotiabank began coverage on shares of Danaher in a research report on Monday, December 23rd. They set a "sector perform" rating and a $265.00 target price on the stock. Jefferies Financial Group reduced their price target on shares of Danaher from $285.00 to $260.00 and set a "buy" rating for the company in a research report on Wednesday, January 29th. Bank of America upgraded shares of Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price objective for the company in a report on Friday, December 13th. Stifel Nicolaus upgraded Danaher from a "hold" rating to a "buy" rating and set a $260.00 price target for the company in a research note on Friday, March 14th. Finally, Guggenheim began coverage on Danaher in a report on Thursday, December 19th. They set a "buy" rating and a $275.00 price target for the company. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $278.24.
Check Out Our Latest Stock Analysis on DHR
Danaher Trading Up 0.4 %
Shares of DHR stock traded up $0.73 during mid-day trading on Wednesday, reaching $175.37. The stock had a trading volume of 1,970,318 shares, compared to its average volume of 3,258,983. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $125.34 billion, a PE ratio of 33.16, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86. Danaher Co. has a 52-week low of $171.30 and a 52-week high of $281.70. The stock's 50-day moving average price is $206.13 and its two-hundred day moving average price is $231.95.
Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period last year, the firm posted $2.09 earnings per share. Equities analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.73%. This is a boost from Danaher's previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. Danaher's dividend payout ratio is presently 24.24%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Recommended Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
